Articles published by Boundless Bio

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 05, 2024

From Boundless Bio

Via Business Wire

Tickers BOLD

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 13, 2024

From Boundless Bio

Via Business Wire

Tickers BOLD

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

May 06, 2024

From Boundless Bio

Via Business Wire

Tickers BOLD

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

April 11, 2024

From Boundless Bio

Via Business Wire

Tickers BOLD

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

April 08, 2024

From Boundless Bio

Via Business Wire

Tickers BOLD

Boundless Bio Announces Pricing of Initial Public Offering

March 27, 2024

From Boundless Bio

Via Business Wire

Boundless Bio Announces Multiple Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

March 05, 2024

From Boundless Bio

Via Business Wire

Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Announces Upcoming Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 04, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Appoints New Board Members and Establishes Clinical Advisory Board

October 02, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors

September 19, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors

September 18, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Appoints Jami Rubin as Chief Financial Officer

July 31, 2023

From Boundless Bio

Via Business Wire

Boundless Bio to Present at the 2023 Jefferies Healthcare Conference

June 01, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification

May 09, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023

April 17, 2023

From Boundless Bio

Via Business Wire

Boundless Bio to Present at the Stifel 2023 Virtual Targeted Oncology Days

April 11, 2023

From Boundless Bio

Via Business Wire

Boundless Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 04, 2023

From Boundless Bio

Via Business Wire

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2023

March 15, 2023

From Boundless Bio

Via Business Wire

Boundless Bio to Participate at Two Upcoming Investor Conferences

November 15, 2022

From Boundless Bio

Via Business Wire

Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges

June 16, 2022

From Boundless Bio

Via Business Wire

Boundless Bio to Present at the 2022 Jefferies Healthcare Conference

June 06, 2022

From Boundless Bio

Via Business Wire

Boundless Bio Appoints Sara Weymer as Vice President, Clinical Operations

June 03, 2022

From Boundless Bio

Via Business Wire

Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022

April 08, 2022

From Boundless Bio

Via Business Wire

Boundless Bio Appoints Klaus Wagner, M.D., Ph.D., as Chief Medical Officer

February 22, 2022

From Boundless Bio

Via Business Wire

Boundless Bio Appoints Amy Berkley, Ph.D., as Vice President, Program Team Leadership and Strategic Alliances

February 07, 2022

From Boundless Bio

Via Business Wire

Boundless Bio to Present at the Guggenheim Oncology Conference

February 02, 2022

From Boundless Bio

Via Business Wire

Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine

January 17, 2022

From Boundless Bio

Via Business Wire

Boundless Bio Appoints Jennifer Lew to its Board of Directors

January 05, 2022

From Boundless Bio

Via Business Wire

Boundless Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Boundless Bio

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.